Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient

Transplantation

Volumn 90, Issue 1, 2010, Pages 98-99

  Herden, Uta ^a   Fischer, Lutz ^a   Schäfer, Hansjörg ^a   Nashan, Björn ^a   Von Baehr, Volker ^b   Sterneck, Martina ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institute of Medical Diagnostics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; SORAFENIB; STEROID;

ADULT; ALCOHOL LIVER CIRRHOSIS; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; PRIORITY JOURNAL; TOXIC HEPATITIS;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; DRUG-INDUCED LIVER INJURY; HEPATITIS C; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PYRIDINES; TREATMENT OUTCOME;

EID: 77954617804     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181daac69     Document Type: Letter

References (5)

1. Llovet JM, Ricci S, Mazzaferro V, et al. Sor-afenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378.
2. Llanos L, Bellot P, Zapater P, et al. Acute hepatitis in a patient with cirrhosis and hep-atocellular carcinoma treated with sorafenib. Am J Gastroenterol 2009; 104: 257.
3. Schramm C, Schuch G, Lohse AW. Sorafenib-induced liver failure. Am J Gas-troenterol 2008; 103: 2162.
4. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714.
5. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12: 426.